News und Analysen
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Sensorion to Present at the 44th Annual J.P. Morgan Healthcare Conference
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
EQS-News: Abivax to be Added to Nasdaq Biotechnology Index
EQS-News: Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings
Humana, Nurses on Boards Coalition Announce New Partnership to Mentor Emerging Nurses
Humana has announced a new partnership with the national Nurses on Boards Coalition (NOBC) to provide mentors for nursing students.
Humana is providing a gift of $110,000 for first-year funding
Sonova strengthens digital health portfolio with SilentCloud™ acquisition, advancing integrated hearing care
EQS-News: Abivax Presents Third Quarter 2025 Financial Results
Silence Therapeutics Announces Leadership Changes
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that Craig Tooman, who
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
EQS-News: Expansion of the Management Board of M1 Kliniken AG
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
EQS-News: Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda® (Pembrolizumab), in the U.S. and Canada
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Sensorion Reports Independent Data Monitoring Committee Raises No Safety Concerns and Agrees to Continue SENS-501’s Audiogene Phase 1/2 Trial
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss
EQS-News: Reorganization of the Eckert & Ziegler Executive Board
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome
Bayer announced today initiation of a Phase IIa clinical trial with BAY 3401016, an investigational monoclonal antibody with potential to block a protein called Semaphorin 3A (Sema3A), which is
EQS-News: Formycon and MS Pharma sign exclusive commercialization partnership for Keytruda® biosimilar candidate FYB206 for the MENA Region
RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints
Bayer, a global leader in radiology, today revealed results from the QUANTI Pediatric study, adding to the pharmacokinetic, safety and efficacy data of the investigational low-dose MRI
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
EQS-News: Eckert & Ziegler and SK Biopharmaceuticals Sign Actinium-225 Supply Agreement
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Molina Healthcare
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Molina Healthcare, Inc. (“Molina” or the “Company”) (NYSE: MOH) and reminds investors of the